Daily briefing: What really works to reduce carbon emissionsA strategic mix of 63 effective climate policies can significantly reduce emissions, averaging a 19% decrease.
Alzheimer's drug that can slow disease gets backing from FDA advisersFDA advisers backed Alzheimer's drug from Eli Lilly, suggesting approval for mild dementia treatment.
FDA advisors strongly back new Alzheimer's drug, despite risks and limitationsFDA advisors recommend approval of Alzheimer's drug donanemab for slowing disease progression.
A Drug to Slow Alzheimer's Is Finally Available. How Are Patients Faring?The Alzheimer's drug lecanemab offers hope with modest benefits and high risks, as strict criteria determine patient eligibility.
FDA approves a second Alzheimer's drug that can modestly slow diseaseFDA approved Eli Lilly's Kisunla for early-stage Alzheimer's, offering modest cognitive decline delay of about seven months.
Alzheimer's drug that can slow disease gets backing from FDA advisersFDA advisers backed Alzheimer's drug from Eli Lilly, suggesting approval for mild dementia treatment.
FDA advisors strongly back new Alzheimer's drug, despite risks and limitationsFDA advisors recommend approval of Alzheimer's drug donanemab for slowing disease progression.
A Drug to Slow Alzheimer's Is Finally Available. How Are Patients Faring?The Alzheimer's drug lecanemab offers hope with modest benefits and high risks, as strict criteria determine patient eligibility.
FDA approves a second Alzheimer's drug that can modestly slow diseaseFDA approved Eli Lilly's Kisunla for early-stage Alzheimer's, offering modest cognitive decline delay of about seven months.